Treatment of Telogen Effluvium
Minoxidil (topical or low-dose oral) is the primary pharmacologic treatment for telogen effluvium, with the choice between formulations depending on extent of involvement and patient preference, while identifying and addressing the underlying trigger remains the cornerstone of management 1.
Treatment Algorithm
First-Line Approach: Identify and Address Triggers
- Investigate common precipitants: emotional stress, acute febrile illness, nutritional deficiencies (iron, ferritin, vitamin D), medications, surgery, or systemic infection 2, 3
- Order targeted laboratory work-up for iron studies, ferritin, vitamin D, and thyroid function
- Correct identified deficiencies and remove offending medications when possible
- Reassure patients: telogen effluvium is typically self-limiting and reversible, with gradual regrowth expected over 3-6 months 3
Pharmacologic Treatment Options
When to treat pharmacologically:
- Patient distress warrants intervention
- Desire to accelerate recovery
- Chronic or persistent telogen effluvium
Minoxidil Selection:
Topical Minoxidil - Consider when:
- Hair loss limited to central scalp or patchy distribution 1
- Patient prefers topical application
- FDA-approved formulations: 2% solution twice daily (women) or 5% foam once daily (women); 5% solution or foam twice daily (men)
Low-Dose Oral Minoxidil (LDOM) - Preferred when:
- Entire scalp involved 1
- Patient compliance concerns with topical application
- Topical minoxidil causes skin irritation 4
- Dosing: 0.25-5 mg daily (most commonly 1-2.5 mg) 4
- Efficacy: 52.4% show clinical improvement, 42.9% stabilization in retrospective studies 5
- Time to resolution: approximately 93 days in COVID-19-related telogen effluvium 6
Pre-Treatment Evaluation for LDOM
Contraindications (do not prescribe):
- Hypersensitivity to minoxidil
- Active cardiovascular disease requiring consultation 4
Precautions (seek cardiology/primary care consultation):
- History of tachycardia or arrhythmia (81.8% expert consensus) 4
- Hypotension (BP <90/60 mm Hg) (77.3% consensus) 4
- Kidney function impairment (88.4% consensus) 4
- Patients on dialysis (88.4% consensus) 4
Baseline evaluation before LDOM:
- Blood pressure measurement
- Heart rate assessment
- Renal function testing
- Cardiovascular history review
Alternative/Adjunctive Therapies
Evidence-based alternatives:
- Botulinum toxin A: Single session injection shows efficacy comparable to multivitamins mesotherapy, with minimal side effects 7
- Multivitamins mesotherapy: Multiple sessions required, equivalent success rates to botulinum toxin 7
Observation alone:
- Most common therapeutic approach in pediatric populations 2
- Appropriate when trigger identified and corrected
- Patient adequately reassured about natural resolution
Key Clinical Pearls
Common Pitfalls to Avoid
- Don't dismiss the diagnosis without visible shedding: In men with short hair, telogen effluvium may go unnoticed despite active disease 8
- Don't overlook nutritional deficiencies: Iron, ferritin, and vitamin D deficiencies are common triggers requiring correction 2
- Don't forget temporal relationship: Telogen effluvium typically manifests 2-4 months (mean 117 days) after the triggering event 6
Expected Outcomes
- Topical vs oral minoxidil: No statistically significant difference in efficacy in controlled trials 1
- Treatment response timeline: Continuous improvement expected at 2-month, 3-month, and 4-month follow-ups 6
- Common side effects: Transient shedding with initiation, hypertrichosis (especially with oral), contact dermatitis with topical (often from propylene glycol) 4
Special Populations
- COVID-19-related telogen effluvium: LDOM demonstrates safety and efficacy, with resolution in approximately 3 months 6
- Pediatric patients: Observation most common; greater evidence-based treatment approaches needed 2
- Post-surgical patients: Consider anesthesia as potential trigger; no specific guidelines exist for prevention 9